Skip to main content
SpringerLink
Log in

Comment on: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 27 December 2016

The Original Article was published on 17 June 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Glund S, Stangier J, van Ryn J, et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study. Clin Pharmcokinet. 2016;55:1–14.

    Article  Google Scholar 

  2. Hernandez I, Baik SH, Pinera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA. 2015;175(1):18–24.

    Google Scholar 

  3. Eikelboom J, Wallentin L, Connolly S, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.

    Article  CAS  PubMed  Google Scholar 

  4. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.

    Article  CAS  PubMed  Google Scholar 

  5. Marino K, Santiago R, Dew RB 3rd, et al. Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis. Pharmacotherapy. 2016;36(10):e160–5.

    Article  CAS  PubMed  Google Scholar 

  6. Rottenstreich A, Jahshan N, Avraham L, et al. Idarucizumab for dabigatran reversal: does one dose fit all? Thromb Res. 2016;146:103–4.

    Article  CAS  PubMed  Google Scholar 

  7. Thorborg C, Horn E, Mofid H, et al. Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus. Br J Anaesth. 2016;117(3):407–9.

    Article  CAS  PubMed  Google Scholar 

  8. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–51.

    Article  PubMed  Google Scholar 

  9. Eikelboom J, Quinlan D, van Ryn J, et al. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132:2412–22.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Christchurch Public Hospital, 2 Riccarton Avenue, Christchurch, New Zealand

    Kirollos S. Kamel, Paul K. L. Chin, Matthew P. Doogue & Murray L. Barclay

  2. University of Otago, Christchurch, 2 Riccarton Avenue, PO Box 4345, Christchurch, New Zealand

    Paul K. L. Chin, Matthew P. Doogue & Murray L. Barclay

Authors
  1. Kirollos S. Kamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul K. L. Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew P. Doogue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Murray L. Barclay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul K. L. Chin.

Ethics declarations

Conflict of interest

Kirollos S. Kamel, Paul K. L. Chin, Matthew P. Doogue and Murray L. Barclay declare that they have no conflicts of interest.

Funding

None received.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamel, K.S., Chin, P.K.L., Doogue, M.P. et al. Comment on: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”. Clin Pharmacokinet 56, 207–208 (2017). https://doi.org/10.1007/s40262-016-0481-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-016-0481-5

Keywords

Search

Navigation